Trial Profile
A Prospective, Multicentre Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) in the Treatment of Patients with a single De Novo Atherosclerotic Lesion.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms PLATINUM-QCA
- 10 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2010 Results will be presented at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, according to a Boston Scientific Corporation media release.
- 03 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.